Arizona Outsourcing Facility Warned for Misbranded, Adulterated Products

Drug Industry Daily
A A
The FDA slapped Phoenix-based outsourcing facility Atlas Pharmaceuticals with a warning letter for adulterated and misbranded drug products as well as numerous CGMP violations stemming from an inspection carried out in August and September 2017.

To View This Article:

Login

Subscribe To Drug Industry Daily